There is new evidence that the immunotherapy drug durvalumab may make chemotherapy more effective for people with inoperable pleural mesothelioma. Researchers recently achieved record mesothelioma survival times with this combination. Mesothelioma is a rare cancer with a poor prognosis. Surgery can sometimes help if it is caught early. But only a small percentage of patients are candidates for mesothelioma surgery. Most have chemotherapy, which is only moderately effective. But new research presented to the nation’s largest gathering of cancer doctors shows the immunotherapy drug durvalumab may help. Doctors at Johns Hopkins combined durvalumab with standard mesothelioma chemotherapy. Study participants lived an average of 8 months longer than is typical with this disease. If further studies confirm the benefit, it could … Continue reading Immunotherapy with Durvalumab: Record Survival in Inoperable Mesothelioma
There is new evidence to support the idea that infections can help fight mesothelioma. Researchers at a Belgium University say mice with mesothelioma had slower-growing tumors and lived longer when they were injected with a virus. The research team used a mouse virus called lactate dehydrogenase-elevating virus. The new study suggests that infections can help fight mesothelioma by activating cancer-killing immune system cells. The study could help doctors understand how to use the immune system to combat malignant mesothelioma in human patients. The Immune System and Mesothelioma The immune system is constantly on the lookout for cells that could turn into cancer. When natural killer cells recognize a potential mesothelioma cell, they destroy it. But mesothelioma cells produce proteins that … Continue reading Infections Can Help Fight Mesothelioma, Study Suggests
Japanese researchers testing photoimmunotherapy for mesothelioma say they used the technology to successfully reduce the size of tumors in mice. Scientists at the National Cancer Institute in the US developed near-infrared photoimmunotherapy (NIR-PIT). It is a new type of cancer immunotherapy that uses a chemical to make some cells more sensitive to light. When light is directed at these cells, they die. In their new study of photoimmunotherapy for mesothelioma, the Japanese team targeted podoplanin. Podoplanin is a glycoprotein. Many mesothelioma tumors overexpress podoplanin. Targeting Mesothelioma Tumors with Light Malignant mesothelioma is a fast-growing membrane cancer caused by asbestos exposure. Standard cancer therapies do not work well for mesothelioma. Cancer researchers around the world are looking for alternative treatments. Immunotherapy … Continue reading Photoimmunotherapy for Mesothelioma Reduces Tumor Volume in Mice
As concern about the novel coronavirus spreads around the world, there could be an unexpected upside to social distancing for mesothelioma patients. Social distancing is the recommendation that people not gather in larger groups. Even in smaller settings, the CDC recommends that people stay at least six feet apart from one another to avoid spreading the virus. The coronavirus disease (COVID-19) is caused by the virus SARS-CoV2. Because humans have not yet built up immunity to SARS-CoV2, it is more likely to make them sick. Mesothelioma patients may have even lower resistance to disease. This is why social distancing for mesothelioma patients is especially important. As people become more aware of the threat to themselves at others, they are less … Continue reading Social Distancing for Mesothelioma Patients: Unexpected Upside?
An international team of scientists has identified a protein biomarker for mesothelioma that appears to shorten survival. The biomarker is CD70. It belongs to the tumor necrosis factor (TNF) family of proteins. New research suggests that patients who express more of this protein biomarker for mesothelioma have faster-growing tumors that are less likely to respond to treatment. High CD70 levels have been linked with tumor aggression in some other types of cancer. This is the first time they have been linked to malignant pleural mesothelioma survival. CD70 and Mesothelioma Prognosis Pleural mesothelioma is a highly aggressive type of tumor. It grows on the membranes around internal organs. Mesothelioma rarely responds to standard cancer treatments. People diagnosed with pleural mesothelioma are … Continue reading Protein Biomarker for Mesothelioma Linked to Shorter Survival
New data suggests first-line Keytruda treatment helps lung cancer patients more than chemotherapy – even if chemotherapy patients add Keytruda later. The news is likely to have implications for people with pleural mesothelioma, too. German researchers presented the data earlier this week at the World Lung Cancer Conference in Barcelona. The presentation was based on three years of the KEYNOTE-024 trial. The trial focused on lung cancer. But Keytruda is also an up-and-coming drug for malignant pleural mesothelioma. Pleural mesothelioma is a lung-related cancer similar to non-small cell lung cancer. Blocking PD-L1 with First-Line Keytruda Treatment Keytruda is the brand name for pembrolizumab. It is an immune checkpoint inhibitor that blocks a protein called PD-L1. To be eligible for first-line … Continue reading First-Line Keytruda Treatment May Support Longer Mesothelioma Survival
There is new evidence that adding a drug called vorinostat to immunotherapy might help relapsed pleural mesothelioma patients. The new study comes from the Moffitt Cancer Center in Tampa. It focused on patients with non-small cell lung cancer. Non-small cell lung cancer is similar to pleural mesothelioma in many ways. The study found that patients who received vorinostat along with an immune checkpoint inhibitor had better results. The findings could be good news for relapsed pleural mesothelioma patients, too. Different Immunotherapy Drugs Vorinostat is sold under the brand name Zolinza. It is a histone deacetylase (HDAC) inhibitor. HDAC inhibitors alter the way proteins are expressed inside cells. They also stimulate the immune system. Immune checkpoint inhibitors (ICIs) like Keytruda also … Continue reading New Hope for Relapsed Pleural Mesothelioma?
Belgian scientists say they are still not sure about the effect of chemotherapy on immunotherapy for mesothelioma. They reached that conclusion after testing several different chemotherapy drugs on mesothelioma cells in the lab. The combination of chemotherapy and immunotherapy is “chemoimmunotherapy”. It aims to harness the unique powers of each treatment approach. A meta-analysis last May called chemoimmunotherapy the “next frontier” in mesothelioma treatment. But the new Belgian study on the effect of chemotherapy on immunotherapy highlights how much doctors still do not know about the combo. Immune Checkpoints Are the Key When it is working properly, the immune system is supposed to find and kill cancer cells before they become mesothelioma tumors. But mesothelioma cells can hide from the … Continue reading Effect of Chemotherapy on Immunotherapy for Mesothelioma
Cancer researchers at Baylor College of Medicine have launched a new mesothelioma immunotherapy trial. The trial combines the cancer drug Opdivo (nivolumab) with injections of a modified virus called MTG201. Baylor scientists are hoping to recruit 12 pleural mesothelioma patients whose cancer has come back after chemotherapy. The treatment combination appeared to work well in mice with mesothelioma. If it works as well in people, this new mesothelioma immunotherapy trial could change the outlook for many people with malignant mesothelioma. How the New Mesothelioma Immunotherapy Trial Will Work Opdivo is the brand name for nivolumab. It blocks a protein called PD-1 in cancer cells. PD-1 is one of the ways that mesothelioma cells evade the immune system. Opdivo is often … Continue reading New Mesothelioma Immunotherapy Trial Now Underway at Baylor
A new kind of mesothelioma treatment called dendritic cell therapy might make other types of treatments even more effective. Right now, chemotherapy with Alimta (pemetrexed) is the only approved therapy for malignant mesothelioma. Many others are in the works. But so far, none of them extend the lives of mesothelioma patients by more than a few months. Dendritic cell therapy for mesothelioma may be different. This novel treatment uses the patient’s own cells to jumpstart the immune system. A Dutch company developed and is testing the new treatment. The data so far suggests that it could boost chemotherapy and help new drugs like Keytruda work better. How Dendritic Cell Therapy Works Dendritic cells are immune system cells that function as … Continue reading Dendritic Cell Therapy for Mesothelioma: Can it Help Other Treatments Work Better?